Concert Pharmaceuticals Inc.

4.31+0.0500+1.17%Vol 380.91K1Y Perf 4.16%
Jun 24th, 2022 16:00 DELAYED
BID4.26 ASK4.36
Open4.28 Previous Close4.26
Pre-Market- After-Market4.36
 - -  0.05 1.16%
Target Price
14.38 
Analyst Rating
Strong Buy 1.00
Potential %
233.64 
Finscreener Ranking
★★★★     54.31
Insiders Trans % 3/6/12 mo.
100/-54/-63 
Value Ranking
★★+     48.57
Insiders Value % 3/6/12 mo.
100/74/64 
Growth Ranking
★★★★     59.06
Insiders Shares Cnt. % 3/6/12 mo.
100/63/51 
Income Ranking
 —    -
Price Range Ratio 52W %
40.37 
Earnings Rating
Neutral
Market Cap200.21M 
Earnings Date
4th Aug 2022
Alpha0.00 Standard Deviation0.20
Beta0.32 

Today's Price Range

4.164.34

52W Range

2.576.88

5 Year PE Ratio Range

-3.807.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
5.12%
1 Month
-7.91%
3 Months
10.80%
6 Months
27.14%
1 Year
4.16%
3 Years
-62.68%
5 Years
-70.34%
10 Years
-

TickerPriceChg.Chg.%
CNCE4.310.05001.17
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
7.40
7.60
0.15
0.19
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-274.90
-270.60
-57 316.90
-
RevenueValueIndustryS&P 500US Markets
32.57M
0.72
222.62
44.81
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.93-1.00-7.53
Q04 2021-0.76-0.95-25.00
Q03 2021-0.76-0.78-2.63
Q02 2021-0.720.16122.22
Q01 2021-0.66-0.67-1.52
Q04 2020-0.73-0.695.48
Q03 2020-0.68-0.6011.76
Q02 2020-0.68-0.4139.71
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.961.03Positive
9/2022 QR-0.87-7.41Negative
12/2022 FY-3.58-3.77Negative
12/2023 FY-2.1011.02Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.96
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume380.91K
Shares Outstanding46.45K
Shares Float42.82M
Trades Count2.51K
Dollar Volume1.62M
Avg. Volume1.06M
Avg. Weekly Volume640.38K
Avg. Monthly Volume1.79M
Avg. Quarterly Volume741.11K

Concert Pharmaceuticals Inc. (NASDAQ: CNCE) stock closed at 4.31 per share at the end of the most recent trading day (a 1.17% change compared to the prior day closing price) with a volume of 380.91K shares and market capitalization of 200.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 71 people. Concert Pharmaceuticals Inc. CEO is Roger D. Tung.

The one-year performance of Concert Pharmaceuticals Inc. stock is 4.16%, while year-to-date (YTD) performance is 36.83%. CNCE stock has a five-year performance of -70.34%. Its 52-week range is between 2.57 and 6.88, which gives CNCE stock a 52-week price range ratio of 40.37%

Concert Pharmaceuticals Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 2.73, a price-to-sale (PS) ratio of 5.73, a price to cashflow ratio of 3.40, a PEG ratio of 2.32, a ROA of -72.71%, a ROC of -86.01% and a ROE of -103.24%. The company’s profit margin is -%, its EBITDA margin is -270.60%, and its revenue ttm is $32.57 Million , which makes it $0.72 revenue per share.

Of the last four earnings reports from Concert Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.96 for the next earnings report. Concert Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Concert Pharmaceuticals Inc. is Strong Buy (1), with a target price of $14.38, which is +233.64% compared to the current price. The earnings rating for Concert Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Concert Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Concert Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.74, ATR14 : 0.48, CCI20 : -63.04, Chaikin Money Flow : 0.16, MACD : -0.01, Money Flow Index : 58.66, ROC : -12.22, RSI : 49.24, STOCH (14,3) : 25.54, STOCH RSI : 0.79, UO : 38.08, Williams %R : -74.46), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Concert Pharmaceuticals Inc. in the last 12-months were: James V. Cassella (Sold 14 742 shares of value $47 379 ), Jeffrey A. Munsie (Sold 6 656 shares of value $20 885 ), Marc E. Becker (Sold 13 960 shares of value $44 805 ), Nancy Stuart (Sold 8 943 shares of value $27 863 ), Richard H. Aldrich (Buy at a value of $999 999), Roger D. Tung (Option Excercise at a value of $23 450), Roger D. Tung (Sold 29 420 shares of value $94 459 ), Thomas G. Auchincloss (Buy at a value of $28 500), Van Christi Heek (Buy at a value of $49 999)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Concert Pharmaceuticals Inc.

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

CEO: Roger D. Tung

Telephone: +1 781 860-0045

Address: 65 Hayden Avenue, Lexington 02421, MA, US

Number of employees: 71

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

67%33%

Bearish Bullish

59%41%

TipRanks News for CNCE

Mon, 23 May 2022 14:05 GMT Concert Pharma (CNCE) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Thu, 12 May 2022 13:25 GMT Concert Pharma (CNCE) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 12 May 2022 04:25 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Concert Pharma (CNCE), Clearside Biomedical (CLSD) and Turning Point Therapeutics (TPTX)

- TipRanks. All rights reserved.

Thu, 05 May 2022 16:45 GMT Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Concert Pharma (CNCE) and OrthoPediatrics (KIDS)

- TipRanks. All rights reserved.

Mon, 25 Apr 2022 00:45 GMT Concert Pharma (CNCE) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits